Kala Pharmaceuticals appoints Pfefer as president and CEO

Tuesday, July 17, 2012 08:09 AM

Kala Pharmaceuticals, a Waltham, Mass.-based developer of products that rapidly penetrate the mucosal barrier to treat a wide range of debilitating diseases, has appointed Guillaume Pfefer, PhD, as president, CEO and member of the board of directors.

Pfefer brings to Kala more than 15 years of experience in the pharmaceutical industry leading commercial, strategic, R&D and industrial operations. Prior to joining Kala, he held a number of ascending leadership positions over a nine-year career at Sanofi Pasteur—most recently serving as general manager of Sanofi Pasteur Mexico. Pfefer also previously held executive management positions with Aventis and Rhone-Poulenc.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs